Sign In
Buy IDXG
$1.75
-0.0100 (-0.568%)
At Close: Jun 03, 2026
Interpace Biosciences Expands Strategic Partnership Activities with Genecast Biotechnology in China
11:55am, Thursday, 05'th Dec 2019
Interpace Bioscience’s subsidiary, Interpace Pharma Solutions today announced that it is continuing to expand a previously announced partnership agreement to jointly develop, promote and offer trans
Interpace Biosciences Launches New Corporate Website
11:55am, Monday, 02'nd Dec 2019
Interpace Biosciences, Inc. (IDXG) announced today that it is launching its new corporate website, “Interpace.com”. Now both the Diagnostics and Pharma Solutions businesses of Interpace are repre
Third Quarter Revenue Grew 34% Over the Prior Year’s Quarter and 25% Year to Date Acquired BioPharma Business in Partnership with Ampersand Diagnostic Test Volume Grew.
Interpace to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results on Wednesday, November 13, 2019
11:55am, Tuesday, 12'th Nov 2019
Interpace (IDXG) announced today that it will report its third quarter 2019 financial results on Wednesday, November 13, 2019 at 4:30 p.m. ET. Interpace will host a conference call and webcast to dis
Interpace Diagnostics Announces Publication of New Data on Thyroid Test Utility
11:55am, Monday, 04'th Nov 2019
Interpace Group (IDXG) Interpace Diagnostics announced today the publication of two peer-reviewed journal articles and one textbook chapter supporting the clinical utility of ThyGeNEXT® when used alo
Interpace to Present Data at the ATA Annual Meeting
10:55am, Tuesday, 29'th Oct 2019
Interpace (IDXG) announced today that it will be presenting new data on the performance of its molecular thyroid products at the upcoming 89th Annual Meeting of the American Thyroid Association (ATA),
